It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.

Each year, more than 200 million catheters are used worldwide to treat vascular diseases, including heart disease and artery ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research ...

Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc ...

BACKGROUND: The ability to predict recovery of left ventricular ejection fraction (LVEF) in response to guideline-directed therapy among patients with nonischemic cardiomyopathy is desired. We sought ...

Ongoing Monitoring and Follow-Up The prognosis (predicted outcome) for ischemic cardiomyopathy depends on how severely ...

Avidity Biosciences Inc. has announced two new precision cardiology development candidates targeting rare genetic cardiomyopathies. AOC-1086 targets phospholamban (PLN) cardiomyopathy and AOC-1072 ...

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with ...

"We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “For many with HCM, the path to diagnosis and ...